DMPI DelMar Pharmaceuticals Inc.

0.41
-0.01  -1%
Previous Close 0.42
Open 0.43
Price To Book 6.83
Market Cap 4,679,059
Shares 11,412,338
Volume 138,791
Short Ratio
Av. Daily Volume 205,382
Stock charts supplied by TradingView

NewsSee all news

  1. DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension

    SAN DIEGO, March 26, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer

  2. DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors

    SAN DIEGO, March 4, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  3. DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors

    SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  4. DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

    SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  5. DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

    SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 further data due at AACR April 24 - 29, 2020. Top-line data due August 2020.
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
Phase 2 further data due at AACR April 24-29, 2020.
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Latest News

  1. DelMar Pharmaceuticals Receives Nasdaq Bid Price Extension

    SAN DIEGO, March 26, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer

  2. DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors

    SAN DIEGO, March 4, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  3. DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors

    SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  4. DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

    SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  5. DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

    SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  6. DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

    SAN DIEGO, Jan. 29, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  7. DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019

    SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  8. DelMar Pharmaceuticals Presents Positive Interim Data of VAL-083 Demonstrating Favorable Outcomes In Both Recurrent and Newly-Diagnosed GBM

    SAN DIEGO, Nov. 25, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,

  9. DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

    SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  10. DelMar Pharmaceuticals to Host Key Opinion Leader Summit on Glioblastoma Multiforme and the Potential for Treatment with VAL-083

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today

  11. DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

    SAN DIEGO, Oct. 24, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  12. MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16th, 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, the MicroCap

  13. DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time

    SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  14. DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  15. DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

    SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  16. DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  17. DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

    SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  18. DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

    VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the

  19. Thinking about buying stock in Aurora Cannabis, American Express, Walt Disney Co, DelMar Pharmaceuticals, or Tilray?

    NEW YORK, Aug. 26, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AXP, DIS, DMPI, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the